{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.45","value":"713.9"},{"groupId":"OG001","spread":"24.47","value":"569.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"PK parameters of Total Anti-TROP2 Antibody\\_Area under the curve","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set:Enrolled participants who have received at least one dose of treatment and had measurable serum concentrations of Dato-DXd. The analysis for AUC was based on the patients with intensive PK collection of each cohort.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody","type":"SECONDARY","unitOfMeasure":"day*ug/mL"}